# A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis

> **NCT05067335** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 327 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05067335
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-21
- **Primary completion:** 2023-11-09
- **Final completion:** 2023-11-09
- **Target enrollment:** 327 (ACTUAL)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067335, "A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05067335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*